A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.

Inclusion CriteriaMen and women diagnosed with stable plaque psoriasis for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator.Deemed by the investigator to be a candidate for phototherapy or systemic therapy.≥ 3% of Body Surface Area (BSA) involvement at Screening Visit and Day 1Dermatology Life Quality Index (DLQI) score > 5 at Screening Visit and Day 1Exclusion Criteria:Target Disease Exceptions:Non-plaque psoriasis (that is, guttate, pustular, erythrodermic, palmoplantar only involvement or drug-induced psoriasis) at Screening Visit or Day 1Other protocol-defined inclusion/exclusion criteria apply.